人才隊(duì)伍
返回列表
楊威
個(gè)人簡(jiǎn)介
“協(xié)和學(xué)者”特聘教授，北京協(xié)和醫(yī)學(xué)院準(zhǔn)聘副教授，中國(guó)醫(yī)學(xué)科學(xué)院病原生物學(xué)研究所課題組長(zhǎng)，國(guó)家衛(wèi)健委病原系統(tǒng)生物學(xué)重點(diǎn)實(shí)驗(yàn)室PI，病原體感染防控教育部重點(diǎn)實(shí)驗(yàn)室PI。曾任北京市第十屆青年聯(lián)合會(huì)委員，中國(guó)醫(yī)學(xué)科學(xué)院青年科學(xué)家創(chuàng)新聯(lián)盟理事會(huì)副理事長(zhǎng)，中國(guó)青年科技工作者協(xié)會(huì)基礎(chǔ)專(zhuān)委會(huì)委員。哈爾濱工業(yè)大學(xué)/哈爾濱醫(yī)科大學(xué)獲醫(yī)學(xué)遺傳學(xué)博士學(xué)位，美國(guó)匹茲堡大學(xué)傳染病學(xué)博士后，主要研究方向?yàn)獒t(yī)學(xué)病毒學(xué)。發(fā)現(xiàn)了HCV輔助受體Occludin、研發(fā)了高效廣譜的SARS-CoV-2中和抗體、深入闡明了HCV和ZIKV等多種病毒的感染與致病機(jī)制、建立了多維度抗病毒藥物研究平臺(tái)等。教育部自然科學(xué)獎(jiǎng)二等獎(jiǎng)第一完成人。作為通訊作者（含第一作者）在《Hepatology》、《Sci Adv》、《Nat Commun》、《Signal Transduct Target Ther》、《Cancer Res》、《J Cell Biol》、《J Virol》等本領(lǐng)域高水平專(zhuān)業(yè)雜志發(fā)表SCI論文40余篇；超10項(xiàng)專(zhuān)利獲授權(quán)；完成新冠病毒納米抗體成果轉(zhuǎn)化1項(xiàng)；作為項(xiàng)目負(fù)責(zé)人獲得國(guó)家重點(diǎn)研發(fā)計(jì)劃、863、973、國(guó)自然重點(diǎn)項(xiàng)目和面上項(xiàng)目等科研課題多項(xiàng)；培養(yǎng)研究生20余名。
研究方向
聚焦醫(yī)學(xué)病毒學(xué)基礎(chǔ)研究和抗病毒藥物研發(fā)，具體包括：
1. 病毒感染與致病機(jī)制： 丙肝病毒的受體發(fā)現(xiàn)與感染機(jī)制研究、寨卡和登革等黃病毒的致病機(jī)制與抗病毒研究等。
2. 抗體藥物研發(fā)：全合成抗體發(fā)現(xiàn)平臺(tái)與AI抗體設(shè)計(jì)平臺(tái)、抗感染與抗腫瘤抗體藥物研發(fā)等。
科研項(xiàng)目
作為項(xiàng)目負(fù)責(zé)人主持“國(guó)家重點(diǎn)研發(fā)計(jì)劃”項(xiàng)目1項(xiàng)，“863” 項(xiàng)目1項(xiàng)，國(guó)家自然基金區(qū)域聯(lián)合基金重點(diǎn)項(xiàng)目1項(xiàng)、面上項(xiàng)目7項(xiàng)，醫(yī)科院創(chuàng)新工程項(xiàng)目1項(xiàng)等。作為課題負(fù)責(zé)人主持“973計(jì)劃”課題1項(xiàng)、“傳染病重大專(zhuān)項(xiàng)”課題1項(xiàng)等。參與其他國(guó)家級(jí)項(xiàng)目多項(xiàng)。
研究成果
一、代表性論文
1. Yang X, Duan H, Liu X, Zhang X, Pan S, Zhang F, Gao P, Liu B, Yang J, Chi X, Yang W. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening. J Virol. 2023 Jul 27;97(7).
2. Chi X, Zhang X, Pan S, Yu Y, Shi Y, Lin T, Duan H, Liu X, Chen W, Yang X, Chen L, Dong X, Ren L, Ding Q, Wang J, Yang W. An ultrapotent RBD-targeted biparatopic nanobodyneutralizes broad SARS-CoV-2 variants. Signal Transduct Target Ther.2022 Feb 9;7(1):44.
3. Lin T, Chi X, Liu X, Pan S, Chen W, Duan H, Zhang X, Yang W. Recombinant Full-Length Hepatitis CVirus E1E2 Dimer Elicits Pangenotypic Neutralizing Antibodies. Front Immunol.2022 Jun 28;13:831285.
4. Zhou L, Zhou J, Chen T, Chi X, Liu X, Pan S, Chen W, Wu T, Lin T, Zhang X, Li YP, Yang W. Identification of Ascomycin against Zika virus infection through screening of natural product library. Antiviral Res. 2021 Dec;196:105210.
5. Chi X, Liu X, Wang C, Zhang X, Li X, Hou J, Ren L, Jin Q, Wang J, Yang W. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat Commun. 2020Sep 10;11(1):4528.
6. Ci Y, Liu ZY, Zhang NN, Niu Y, Yang Y, Xu C, Yang W, Qin CF, Shi L. Zika NS1-induced ER remodeling is essential for viral replication. J Cell Biol. 2020 Feb 3;219(2).
7. Zhou J, Chi X, Cheng M, Huang X, Liu X, Fan J, Xu H, Lin T, Shi L, Qin C, Yang W. Zika virus degrades the ω-3fatty acid transporter Mfsd2a in brain microvascular endothelial cells and impairs lipid homeostasis. Sci Adv. 2019 Oct 23;5(10):eaax7142.
8. Xu H, Cheng M, Chi X, Liu X, Zhou J, Lin T, Yang W. High-Throughput Screening Identifies Mixed-Lineage Kinase 3 as a Key Host Regulatory Factor in Zika Virus Infection. J Virol. 2019Aug 28;93(18).
9. Fan J, Cheng M, Chi X, Liu X, Yang W. A Human Long Non-coding RNA LncATV Promotes Virus Replication Through Restricting RIG-I-Mediated Innate Immunity. Front Immunol. 2019 Jul 19;10:1711.
10. Cheng M, Niu Y, Fan J, Chi X, Liu X, Yang W. Interferon down-regulation of miR-1225-3p as an antiviral mechanism through modulating Grb2-associated binding protein 3 expression. J Biol Chem. 2018Apr 20;293(16):5975-5986.
11. Li D, Cheng M, Niu Y, Chi X, Liu X, Fan J, Fan H, Chang Y, Yang W. Identification of a novel human long non-coding RNA that regulates hepatic lipid metabolism by inhibiting SREBP-1c. Int J Biol Sci. 2017 Feb 25;13(3):349-357.
12. Chi X, Niu Y, Cheng M, Liu X, Feng Y, Zheng F, Fan J, Li X, Jin Q, Zhong J, Li YP, Yang W. Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain. Sci Rep. 2016 Apr 28; 6:25224.
13. Li X, Niu Y, Cheng M, Chi X, Liu X, Yang W. AP1S3 is required for hepatitis C virus infection by stabilizing E2 protein. Antiviral Res. 2016 Jul; 131:26-34.
14. Yang W, Zhang M, Chi X, Liu X, Qin B, Cui S. An intramolecular bond at cluster of differentiation 81ectodomain is important for hepatitis C virus entry. FASEB J. 2015 Oct;29(10): 4214-26.
15. Niu Y, Si Y, Li Y, Chi X, Li X, Liu X, Li D, Cheng M, Fan J, Si S, Yang W. A novel small-molecule inhibitor of hepatitis C virus replication acts by suppressing signal transducer and activator of transcription 3. J Antimicrob Chemother. 2015 Jul; 70(7):2013-23.
16. Cheng M, Si Y, Niu Y, Liu X, Li X, Zhao J, Jin Q, Yang W. High-throughput profiling of alpha interferon- andinterleukin-28B-regulatedmicroRNAs and identification of let-7s with anti-hepatitis C virus activity by targeting IGF2BP1. J Virol. 2013 Sep; 87(17):9707-18.
17. Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, LiX, Chen Y, Yang W. Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus ANS5A. J Virol. 2013 Feb; 87(3):1649-57.
18. Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. A humanclaudin-1-derived peptide inhibits hepatitis C virus entry. Hepatology. 2012 Aug; 56(2):507-15.
19. Cheng M, Si Y, Yang Y, Liu X, Gong Q, Zhao J, Niu Y, Li X, Jin Q, Yang W. Recombinant human interleukin 28B: anti-HCV potency, receptor usage and restricted cell-type responsiveness. J Antimicrob Chemother. 2012 May; 67(5):1080-7.
20. Liu X, Wang T, Wakita T, Yang W. Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology. 2010 Mar1; 398(1):57-67.
21. Liu S#, Yang W#, Shen L, Turner JR, Coyne CB, Wang T. Tight junction proteins claudin-1and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol. 2009 Feb; 83(4):2011-4.
22. Yang W, Hood BL, Chadwick SL, Liu S, Watkins SC, Luo G, Conrads TP, Wang T. Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology. 2008 Nov; 48(5):1396-403.
23. Yang W, Qiu C, Biswas N, Jin J, Watkins SC, Montelaro RC, Coyne CB, Wang T. Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. J Biol Chem. 2008 Mar 28; 283(13):8643-53.
24. Yang W, Zhang Y, Li Y, Wu Z, Zhu D. Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 beta pathway and is antagonized by insulin-like growth factor 1. J Biol Chem. 2007 Feb 9; 282(6):3799-808.
25. Yang W, Chen Y, Zhang Y, Wang X, Yang N, Zhu D. Extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway is involved in myostatin-regulated differentiation repression. Cancer Res. 2006 Feb 1; 66(3):1320-6.
二、科技獎(jiǎng)勵(lì)
2017年，教育部自然科學(xué)獎(jiǎng)二等獎(jiǎng)，《丙型肝炎病毒復(fù)制機(jī)制與抗病毒研究》，第一完成人
三、成果轉(zhuǎn)化
2020年，新冠病毒中和性納米抗體成果轉(zhuǎn)化。
研究生培養(yǎng)
已培養(yǎng)博士生畢業(yè)7人、碩士畢業(yè)生3人，聯(lián)合培養(yǎng)畢業(yè)生2人，大部分畢業(yè)生在國(guó)家級(jí)科研院所和大學(xué)從事科研教學(xué)工作，部分畢業(yè)生在海外學(xué)習(xí)或企業(yè)工作。在讀博士生5人，碩士生3人。